AMH is a genuinely informative biological signal - it falls to very low levels years before the final period, and it predicts the timing of menopause better than FSH does at a group level.
But it is not currently reliable for telling one individual woman her personal timeline. Even using a highly sensitive research-grade test, a very low AMH result only gave about a 51 to 79 percent probability of reaching the final period within a year, depending on age, and commercial tests are less sensitive than that. No major guideline currently endorses AMH for diagnosing perimenopause or timing an individual woman's menopause.
The disagreement is genuinely about readiness for individual clinical use, not about whether AMH is biologically meaningful - both sides agree it falls years before the final period.
What the research shows, and which source each finding rests on
AMH falls to low or undetectable levels years before the final menstrual period and is the most promising single biomarker for predicting age at natural menopause at the group level: a systematic review found hazard ratios of 5.6-9.2 for AMH predicting time to menopause across six studies.
The same review's verdict: models 'do not predict the extremes of menopause age very well and have wide prediction interval,' and the markers 'clearly need improvement before they can be used for individual prediction of menopause in the clinical setting.'
In SWAN (1,537 women) using an ultrasensitive research assay, very low AMH (under 10 pg/mL) gave a 51% probability of reaching the final period within 12 months for women under 48, rising to 79% for women 51 and over; high AMH (over 100 pg/mL) gave a 90-97% probability of NOT reaching the final period within 12 months; AMH outperformed FSH for 24-month prediction.
Where the real disagreement is
Each position is shown with its own sources. A position listed here is not necessarily the accepted view.
Not ready for individual use
NICE NG23 and the main systematic review on the topic
The review that established AMH's group-level predictive power also concluded prediction intervals are wide, individual extremes are poorly predicted, and commercial assays are less sensitive than the research assays that produced the promising data, so no major guideline currently endorses it for timing an individual woman's menopause.
Increasingly informative, dismissal is outdated
researchers behind the newer SWAN analysis, and some fertility-adjacent clinicians
A large SWAN analysis found AMH beats FSH for predicting the final period within 24 months and gives clinically meaningful probability ranges at the extremes, particularly for ruling menopause out in the near term with a high AMH result.
What would settle it: Prospective validation of individual-level prediction intervals using commercially available, not just research-grade, assays, tied to a demonstrated decision benefit, such as guiding contraception timing.
What is really going on here
- Is the AMH probability I'm being quoted from a highly sensitive research assay, or the kind of commercial test I would actually get?
- Does a single AMH result change any actual decision I need to make, or is it interesting information without a clear next step?
Questions for your doctor
- What would an AMH result actually change about my care plan?
- Is this the same sensitive assay used in the research studies, or a standard commercial test?
- Are there guideline-supported reasons for me specifically to get this test?
Questions with no answer yet
Would a commercially available AMH test, rather than the highly sensitive research assay used in the strongest studies, give a woman a similarly useful probability range for her own timeline?
Not directly studied yetNo research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.
What is known: The most informative AMH prediction data comes from an ultrasensitive research assay. Commercial tests are known to be less sensitive, and no study has directly validated the same prediction bands using the commercial assay a woman would actually receive in practice.
What would test it: Prospective validation of individual-level prediction intervals using commercially available assays specifically, rather than research-grade ones, tied to a demonstrated decision benefit such as guiding contraception timing.
Does giving a woman a probabilistic AMH result actually change a decision she makes, such as when to stop contraception or how to plan around symptoms, or does it mainly function as interesting information without a clear next step?
Not directly studied yetNo research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.
What is known: No guideline currently endorses AMH for this purpose, and while some clinicians use it pragmatically for specific decisions like contraception timing, no study has tested whether receiving an AMH result changes what a woman or her clinician actually decides to do.
What would test it: A decision-impact study comparing outcomes or choices in women who receive an AMH result against those who do not, for a specific decision such as contraception cessation timing.
Sources
- 1.Can we predict age at natural menopause using ovarian reserve tests or mother's age at menopause? A systematic literature review.Depmann M, Broer SL, van der Schouw YT, et al. Can we predict age at natural menopause using ovarian reserve tests or mother's age at menopause? A systematic literature review. Menopause 2016;23(2):224-32. · Systematic review or guideline
- 2.Antimullerian Hormone and Impending Menopause in Late Reproductive Age: The Study of Women's Health Across the Nation.Finkelstein JS, Lee H, Karlamangla A, et al. Antimullerian hormone and impending menopause in late reproductive age: the Study of Women's Health Across the Nation. J Clin Endocrinol Metab 2020;105(4):e1862-71. · Observational study
- 3.NICE. Menopause: identification and management. NICE guideline NG23 (2015, updated November 2024), section 1.2.Systematic review or guideline
The letter grades the type of study behind a claim, not the answer itself.
This page is general information based on published research and public sources. It is not medical advice and not a personal assessment, and it does not replace a conversation with your doctor. Peritale is a wellness product, not a medical device, and is not intended to diagnose, treat, cure or prevent any disease. For any medical question, speak with a licensed clinician.
You are not imagining it
In about seven minutes on your phone, Peritale reads five signal systems and maps your symptoms, so you can see that what you feel is real, follow your hormonal transition over time, and walk into your doctor ready to ask for the care you deserve. Your first check is free, no credit card.
Start Free MappingRelated questions
- Is there a test for perimenopause?
- Why did my doctor say my hormones are normal, when I feel terrible?
- How many doctors do women typically see before someone finally tells them it's perimenopause?
- I read that most women with menopause symptoms never seek help - is that really true?
- If there's no blood test, how is perimenopause actually diagnosed?
- Why do so many doctors seem to know so little about menopause?
- Back to topic: Spotting perimenopause, hormone testing and the care gap